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ABSTRACT
As patents on many high-selling biological medicines are expiring, non-innovator versions, such as
biosimilars, may enter this multi-billion dollar market. This study aims to map patents and patent
applications for innovator as well as biosimilar monoclonal antibodies in Europe, and investigates
legal challenges associated with patenting the innovator product and alleged infringing activities,
focusing on consequences for biosimilar developers. Via an exploratory literature review in PubMed
and a database analysis in Darts-ip, Derwent Innovation, and Espacenet, an overview of basic patents
and exclusivity rights for some of the best-selling biologicals is given, supplemented with a detailed
analysis of patents taken during the medicine’s life cycle via three specific case studies (trastuzumab,
bevacizumab, cetuximab). Case law was used to determine which patents were viewed by biosimilar
developers as blocking market entry. For the selected monoclonal antibodies, the key protection
instruments appeared to be the basic patent and the additional protection provided by
a supplementary protection certificate. We observed that additional patents filed after the basic patent
are hard to obtain and often insufficient in blocking market entry of biosimilars, but can in some cases
be a substantial hurdle for biosimilar developers to overcome in patent litigation cases or to invent
around, creating uncertainty on the launch date of a biosimilar on the market. These hurdles, however,
seem to be surmountable, given that many cases were won by biosimilar developers. Also, biosimilars
can be protected by filing new patents and these mainly pertain to new formulations.
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1. Introduction
In return for innovation, pharmaceutical companies can be
rewarded different intellectual property (IP) rights. Different
types of IP rights exist that can be used by pharmaceutical
companies to secure a period of exclusivity to recover invest-
ments from a long and costly research and development
program, i.e., patents, copyrights, design rights, trademarks,
and other IP protection mechanisms such as trade secrets.1,2
Patents, which are territorial and temporally exclusive rights
for inventions that are new, inventive, and industrially applic-
able, are considered the main instruments for protecting IP
related to pharmaceuticals.3-5 In return for this exclusivity, the
invention shall be disclosed to the public in a sufficiently clear
and complete way.5
In Europe, a patent can be applied for at a national level,
with the aim to obtain a patent in one country, or a single
central application can be filed at the European Patent Office
(EPO) with the aim to obtain a European patent that can be
valorized in the countries of interest indicated in the
European patent.2 The basis for patent law in Europe is
provided by the enactment of the European Patent
Convention (EPC).5 As indicated in Article 2 of the EPC,
a European patent shall in each of the Contracting States act
as a national patent. The patentability of biotechnological
inventions, including biotechnological medicines, is further
regulated by Chapter V of the EPC (Rules 26–34) that inte-
grates Directive 98/44/EC on the legal protection of biotech-
nological inventions.6,7 The patent (application) grants its
owner the right to exclude third parties from commercial
exploitation of the invention without its consent. In Europe,
a patent has a maximal duration of 20 y from the filing date of
the application, though after fulfillment of specific criteria, an
additional period of protection can be obtained for a market
authorized product via a national supplementary protection
certificate (SPC). A divisional patent application can be filed
as long as the parent application is pending, and is often filed
when the parent application does not comply with the concept
of ‘unity of invention’.8 The divisional application should not
extend the scope of the subject matter of the parent patent
(Article 76 of the EPC). The scope of protection of a patent is
determined by its claims and its validity can be challenged via
opposition procedures at the European level up to 9 months
after publication of the mention that the patent has been
granted by the EPO; at a later stage the validity can be
challenged nationally in a law suit before a national court.9
Decisions on granting or opposition made by the EPO can be
challenged by those affected by the decision via appeal proce-
dures at the EPO level.
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In general, in the course of a medicine’s life cycle, devel-
opers of medicines can try to protect their product in different
ways. At the start, if the medicine is based on a new and
inventive compound found to be the invention, this com-
pound can be considered for patenting as such, often first
via a more generic structure covering a group of structurally
related compounds. Later, a selection invention can be
claimed if a specific form of the active compound can be
demonstrated to be in some way superior over the previously
claimed group of compounds. Also, new salt forms, com-
pounds with a different crystal structure or with a reduced
particle size may be deemed patentable, provided that they
possess unexpected advantages over existing compounds.9
A novel and inventive synthetic process that is used to pro-
duce the active compound, and different steps of the manu-
facturing process of a medicine may be patented if they
comply with the patentability criteria. Even if the compound
is known or previously patented, a patent can also be applied
for on a specific formulation of the medicine, or on the
combination with one or more other active pharmaceutical
ingredients, provided that unexpected properties can be
demonstrated. Later in the development process, novel and
inventive administration routes, dosage regimens, and indica-
tions can possibly be patented.2,5 A “method of treatment” as
such is however excluded from patentability to guarantee that
physicians are not obstructed in providing care.
These same principles apply to the patenting of therapeutic
antibodies although some specifics to the patenting of anti-
bodies must be taken into consideration. More generic pro-
tection for antibodies has been sought in several ways, i.e.,
based on reference to its target specificity, by target-
independent functional properties, by epitope, by target-
dependent functional properties, or as the result of a process
(product-by-process claim).10 Where protection is to be lim-
ited to one specific monoclonal antibody with particular
properties, this can be characterized by its sequence, or by
reference to the deposit of the hybridoma that produces it.10
Patentability of an antibody highly depends on whether the
antigen it binds or a similar antibody (in generic, polyclonal,
or monoclonal form) is part of the prior art.11 Many thera-
peutically interesting targets are already known and the mere
production of an antibody against such a target is now no
longer considered inventive by the EPO.12 A new character-
istic, leading to unexpected advantages over previously
described antibodies, would then be needed to claim an
inventive step.11,12 Broad patent protection can be sought
via functional claims, but even if granted by the EPO, these
are more easily challenged by competitors.12,13 Structural
claims on the other hand offer narrow protection, but can
still effectively prevent the entry of non-innovator copies to
the market.12,13
Obtaining a patent or other exclusivity rights on
a medicine does not entitle the patent holder to commercia-
lize this medicine. For this, it also has to comply with, for
instance, regulatory requirements such that a marketing
authorization for the medicine is obtained, followed by
a successful market access phase. As developing a new, inno-
vative drug may cost up to US$ 2.6 billion14 and time to
market of a medicine from first patenting can take 10 y or
longer, valuable time to receive a return on the investment is
often substantially reduced. Therefore, upon receiving mar-
keting authorization of a medicine, 8 y of data exclusivity and
additional 2 y of market exclusivity are granted, during which
the company may stop producers of generic or biosimilar
medicines from referring to their data file and entering the
market, respectively.15,16
In addition to data and market exclusivity for a registered
pharmaceutical product, where the product is covered by
a patent, an SPC can be applied for by the patent holder to
extend protection of the active pharmaceutical ingredient
after expiry of the basic patent. While in Europe this is not
a patent extension, an SPC will confer to the specific-
registered medicine the same rights as the initial patent.17
The SPC can only be granted for products that are at the
moment of application protected by a patent and authorized
for use in the European Union, and the duration of the SPC is
determined by Article 13 of the SPC Regulation to be equal to
the period between the filing date of the patent and the date of
first marketing authorization of the product minus 5 y, with
a maximum duration of SPC protection of 5 y in total.18
A one-time extension of 6 months can be granted when
submitting results from studies included in the pediatric
investigation plan (Article 13(3) of the SPC Regulation).
Balancing access to innovation and sustainability of the
healthcare system are ongoing concerns for many European
countries.19 As shown by Urquhart,20 monoclonal antibodies
dominated the top 10 best-selling medicines in 2017, and
a continued increase in both market share and expenditure
can be expected.21 However, patents on many high-selling
biological medicines are expiring or have expired, opening
this multi-billion market to competitors. Competition from
biosimilar medicines, which are similar to a reference product
in terms of quality, safety, and efficacy,22 may reduce treat-
ment costs and help healthcare systems to sustain limited
healthcare budgets or increase patient access to treatment.23
Since the development of a legal and regulatory framework for
marketing authorization of biosimilars in 2005, already more
than 50 biosimilars in different therapeutic classes have been
approved for use in the European Union, including epoetins
and insulins.16,24,25 Since 2013, originator monoclonal anti-
bodies have also been exposed to competition from
biosimilars.26 Authorization dates of innovator and biosimilar
monoclonal antibodies and fusion proteins in Europe are
shown in Table 1.
According to research by Rader et al.,28 patents are the
main determinant for innovators to guarantee market exclu-
sivity, at the same time blocking market entry of biosimilars.
Previous research also shows that patent disputes between
companies may cause uncertainty on the validity of an inno-
vator’s patent, and may at the same time influence the launch
date of the biosimilar, as companies will not risk a product
launch until disputes are resolved.26 The launch date is also
influenced by strategies for prolongation of exclusivity rights
of the company that developed the innovator product, such as
filing a patent for a new indication, formulation, or dosage
regime.10 Biosimilar developers can, however, use new pro-
duction techniques to efficiently produce their product, which
may be patentable. Patenting a new formulation may also be
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possible. The European Medicines Agency (EMA) does not
require the formulation of the biosimilar to be identical to
that of the reference product.29
In this study, we had two objectives. First, we wanted to
map both patents and patent applications for a selection of
biological molecules that currently represent (off-patent)
innovator as well as biosimilar monoclonal antibodies in
Europe. Second, we aspired to investigate legal challenges
associated with patenting the innovator product and alleged
infringing activities, specifically focusing on consequences for
developers of biosimilar medicines.
This is the first study that provides an overview of basic
patents and exclusivity rights for some of the best-selling
biological products, and that carries out a detailed analysis
of patenting along the medicine’s life cycle via specific case
studies to determine which patents were effectively used to
hinder companies developing a biosimilar.
2. Results
Results of the literature review and database analysis are
structured in two parts. First, an overview is given on the
basic patent and other exclusivity protections of the mole-
cules that are included in Table 1. Second, a detailed analy-
sis of patents and their legal challenges are presented for the
innovator product in chronological order and throughout its
life cycle for three cases: trastuzumab, bevacizumab, and
cetuximab. These case studies were selected as patent filing
strategies for adalimumab, etanercept, infliximab, and ritux-
imab were already discussed in the literature,30-32 and rani-
bizumab and eculizumab were found less relevant to study
since both molecules are still patent-protected and have no
approved biosimilars. We focus on the most crucial patents,
i.e., the basic patent and patents that were the subject of
a patent litigation case with a company that we believe was
developing a biosimilar. A more complete overview of iden-
tified patents for each case study can be consulted in the
Appendices. Reference is made to possibilities of biosimilar
developers to protect their product via patents.
2.1. Overview of basic patents and other exclusivity
protections
For a selection of nine molecules, Table 2 lists regulatory
market exclusivities, basic patents, relevant SPCs, other exclu-
sivity rights, the date of end of protection, and the total years
that the product was protected since marketing authorization.
Listed SPCs are valid for the United Kingdom (UK),
Germany, and/or France. In case different expiry dates were
found (a difference of 1 d may occur, depending on calcula-
tions by national patent offices), the latest date is shown.
Protected years since the approval of the selected molecules
(covering both patent protection and regulatory exclusivity
rights) range from 10 y for cetuximab to 17 y for
Table 1. Innovator monoclonal antibodies and fusion proteins for which biosimilars are being developed (selection) or authorized in the European Union
(March 2020), and patent and other exclusivity rights’ expiry dates in the European Union.25,27
Active
substance
Brand name
innovator
MAH
innovator
Date of authorization
innovator
Patent and exclusivity
expiry EU
Brand name
biosimilar
MAH
biosimilar
Date of authorization
biosimilar
Adalimumab Humira® AbbVie 08/09/2003 2018 Amgevita® Amgen 22/03/2017
Imraldi® Samsung
Bioepis
24/08/2017
Halimatoz®/Hefiya®/
Hyrimoz®
Sandoz 26/07/2018
Hulio® Mylan 16/09/2018
Kromeya®/Idacio® Fresenius
Kabi
01/04/2019
Amsparity® Pfizer 12/02/2020
Bevacizumab Avastin® Roche 12/01/2005 2022 Mvasi® Amgen 15/01/2018
Zirabev® Pfizer 13/02/2019
Etanercept Enbrel® Pfizer 02/02/2000 2015 Benepali® Samsung
Bioepis
14/01/2016
Erelzi® Sandoz 23/06/2017
Infliximab Remicade® Janssen
Biologics
13/08/1999 2015* Remsima® Celltrion 10/09/2013
Inflectra® Hospira
(Pfizer)
10/09/2013
Flixabi® Samsung
Bioepis
26/05/2016
Zessly® Sandoz 18/05/2018
Rituximab MabThera® Roche 02/06/1998 2013 Truxima® Celltrion 17/02/2017
Rixathon®/Riximyo® Sandoz 15/06/2017
Ritemvia®/Rituzena®/
Blitzima®
Celltrion 13/07/2017
Trastuzumab Herceptin® Roche 28/08/2000 2014 Ontruzant® Samsung
Bioepis
15/11/2017
Herzuma® Celltrion 09/02/2018
Kanjinti® Amgen 16/05/2018
Trazimera® Pfizer 26/07/2018
Ogivri® Mylan 12/12/2018
Cetuximab Erbitux® Merck KGaA 29/06/2004 2014 - - -
Eculizumab Soliris® Alexion 20/06/2007 2020 - - -
Ranibizumab Lucentis® Novartis 22/01/2007 2022 - - -
*: In some European countries, biosimilar infliximab was launched in 2013.
MAH: Marketing authorization holder; EU: European Union; -: Patent and other exclusivity rights are not yet expired for these products.
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bevacizumab. Average protection on the market seems to be
around 15 y. Except for rituximab, all molecules were granted
an SPC in UK, Germany, and/or France. As the development
time from patent filing to marketing authorization of ritux-
imab was only 5 y, the calculation of a potential SPC period
would give zero additional years of protection.
2.2. Case study on trastuzumab
Trastuzumab is a humanized monoclonal antibody used in
the treatment of breast and gastric cancer, where tumor cells
overexpress the protein human epidermal growth factor
receptor 2 (HER2, or also named HER2/neu, ErbB2 or
c-ErbB-2).38 In Europe, trastuzumab has been marketed by
Roche under the trade name Herceptin® since 2000. Patent
and regulatory exclusivities on Herceptin® as an intravenous
formulation expired on July 29, 2014. Since 2017, several
trastuzumab biosimilars have been approved for use in the
European Union, i.e., Ontruzant® (Samsung Bioepis, 2017),
Herzuma® (Celltrion, 2018), Kanjinti® (Amgen, 2018),
Trazimera® (Pfizer, 2018), and Ogivri® (Mylan, 2018).25
The development of trastuzumab by Genentech (since 2009
part of Roche) builds on the earlier patent of Protein Design
Labs, now called PDL BioPharma, on a method for producing
humanized antibodies, i.e., EP0451216, filed on December 28,
1989. Later, Protein Design Labs agreed to a license on the
granted patent to Genentech for the development and com-
mercialization of, amongst others, Herceptin®,39,40 in return
for royalties on the sales. Also, Genentech itself was at that
time actively performing research in this field; as early as 1984
Genentech applied for a European patent claiming mouse-
human chimeric antibodies (Genentech’s Cabilly patent
family, EP0125023). This patent was granted in 1991 and
was eventually maintained in amended form in 2002 after
opposition by several companies, including Protein Design
Labs, on grounds of lack of novelty, lack of inventive step,
insufficient disclosure, and added subject matter.
On June 15, 1992, Genentech filed EP0590058, the basic
patent related to trastuzumab, which claims several sequences
of humanized heregulin antibodies and was later complemen-
ted with additional protection via an SPC. Two divisional
applications were filed off of this patent: EP1400536, claiming
a method for making humanized antibodies, and EP0940468,
claiming a humanized antibody variable domain, but both
applications were withdrawn by the company just before the
20-y patent term expired.
Genentech also investigated stable monoclonal antibody for-
mulations and filed on July 23, 1996 a patent application for
a specific freeze-dried formulation of, amongst other monoclo-
nal antibodies, trastuzumab, which can be used for subcutaneous
administration after reconstitution, i.e., EP0845997. However,
the application was withdrawn after the Examining Division of
the EPO instructed Genentech to address the EPO requests via
changes to one of the divisional applications. Two divisional
applications were filed: EP1516628, claiming a specific freeze-
dried formulation of, amongst other monoclonal antibodies,
trastuzumab, and EP2275119, claiming a specific freeze-dried
formulation of an anti-HER2 antibody used in the treatment of
cancer where tumor cells overexpress the HER2 receptor. These
divisional patents were granted in August and September 2013,
respectively, and were both subject to opposition, which was
rejected for each in 2016 and the patents were maintained with
only a few months left before patent expiry. However, earlier, in
2015, the Norwegian counterpart of the first-mentioned divi-
sional EP1516628, NO323557, had already been invalidated by
biosimilar developer Hospira (since 2015 part of Pfizer). Also in
the UK, Hospira successfully invalidated the two divisional
patents in 2016 based on lack of inventive step (obviousness).
The use of trastuzumab for the treatment of malignant
breast cancer characterized by overexpression of ErbB2
(HER2) in combination with a taxoid, for example paclitaxel
or docetaxel, was patented by Genentech in EP1037926 on
December 10, 1998. The grant of this patent was opposed by
several parties that were of the opinion that the invention was
not new, inventive or sufficiently disclosed. After rejection of
an appeal filed by Genentech to the negative decision of the
Opposition Division of the EPO, the patent was revoked based
on grounds of lack of inventive step on February 7, 2018, only
10 months before the end of patent term. Shortly after the start
of the appeal procedure in August 2016, Pfizer, which was
developing a trastuzumab biosimilar, started a patent litigation
case in Belgium with the aim to invalidate the patent. However,
the proceedings were suspended, pending the decision of the
EPO in the appeal procedure. On the other hand, Hospira was
successful in invalidating the patent in the UK based on lack of
inventive step on November 30, 2016. Several divisional patent
applications (EP1947119, EP2275450, and EP2277919) were
filed from this application, each of which was later abandoned.
On May 3, 1999, EP1075488 was filed by Genentech,
proposing a protein purification method via ion exchange
chromatography. The patent was granted but opposed by
Novo Nordisk on grounds of lack of novelty, lack of inventive
step and insufficiency of disclosure, and was maintained in an
amended form. Two divisional applications had been filed.
The first one is EP1308455, claiming a composition compris-
ing anti-HER2 antibodies with a certain amount of acidic
variants (obtained after an ion exchange chromatography
step), which is viewed as a patent on a formulation, and
seen by many biosimilar developers as a potential threat to
market entry. The EPO revoked this patent in opposition
based on lack of novelty, but the decision was overturned in
appeal and the patent was maintained in unamended form in
2015. However, in 2014, Hospira had already obtained an
invalidation of the UK patent at the UK High Court of
Justice based on lack of novelty and lack of inventive step,
at the same time receiving a declaration of non-infringement
for their trastuzumab formulation. In 2018, in a court case in
Belgium against Pfizer (developer of Trazimera®), the patent
was deemed invalid based on lack of novelty. Also in 2018, the
German court decided that a biosimilar of Celltrion,
Herzuma® (marketed by Mundipharma), did not infringe
Genentech’s patent. In 2019, the Dutch and the Belgian
court were of the same opinion. Also in 2019, Samsung
Bioepis (Ontruzant®) and Amgen (Kanjinti®) invalidated the
German counterpart based on lack of novelty and inventive
step. MSD, which is marketing trastuzumab biosimilar
Ontruzant®, developed by South Korean company Samsung
Bioepis, was ruled not to infringe Genentech’s patent in
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Sweden and Finland in 2019. A second divisional application
filed off of EP1075488 was EP1308456, claiming antibody
purification by ion exchange chromatography, and claiming,
in contrast to the parent patent, a specific amount of antibody
to be loaded onto the resin. No opposition was filed against
the granted patent.
On May 9, 2000, Genentech claimed the use of an anti-
ErbB2 antibody in the treatment of cancer where tumor cells
overexpress the ErbB2 protein, before or after surgical
removal of the tumor (EP1187632). This patent was revoked
based on lack of inventive step after successful opposition of
Teva, which was co-developing trastuzumab biosimilar
Herzuma® with Celltrion, and subsequent rejection of the
appeal from Genentech.
Later that year, on August 25, 2000, Genentech claimed in
EP1210115 a dosing schedule for the treatment of breast
cancer with anti-ErbB2 antibodies. This patent was revoked
in 2016 on the grounds of lack of sufficient disclosure of the
invention after opposition of several biosimilar developers. In
2015, the England and Wales Court of Appeal had already
decided to dismiss the appeal of Genentech to the invalidation
of the patent in a court case against Hospira (Pfizer) on
grounds of lack of inventive step, and thus the patent was
declared invalid for the UK. Two divisional applications were
filed: 1) EP2111870 (the application was withdrawn in 2018 in
an appeal against the decision of the Examining Division to
refuse the application based on grounds of lack of inventive
step, insufficient disclosure, and extension beyond the content
of the parent patent), and 2) EP2110138 (the application was
withdrawn in 2015 after a negative communication from the
Examining Division, in which they stated that this application
involved double patenting and in addition lacked sufficient
disclosure).
On May 18, 2001, Genentech filed EP1282443 on the use of
an anti-HER2 antibody for cancer patients tested to have an
amplified her2 gene and HER2 overexpression on tumor cells.
The patent was revoked in 2016 after an opposition procedure by
BioGeneriX and Teva, active in the development of biosimilars,
and the appeal of Genentech was subsequently rejected when it
withdrew all claim requests, stating that it no longer approved
the text of the granted patent. One divisional application had
been filed, EP2116262, claiming a method to identify patients
who are likely to respond to treatment with an anti-HER2 anti-
body, but this application was withdrawn by the applicant in
2019, after a warning from the Examining Division that the
application would be refused based on grounds of lack of inven-
tive step and insufficient disclosure.
In addition to the patents previously discussed, a patent on
a subcutaneous formulation and two more patents on protein
purification and prevention of disulfide bond reduction were
found relevant for Herceptin® and can be consulted in Table A1.
As detailed earlier, companies developing biosimilars may
also seek protection of inventions via patents. Patents on new
formulations of trastuzumab have been identified. On April 16,
2015, Mylan and partner Biocon filed an application on stable
protein formulations comprising a molar excess of sorbitol,
which includes trastuzumab (EP3131584). This application is
still under examination. On August 12, 2016, Amgen filed
a patent application on the production of an aqueous solution
for trastuzumab and other molecules, and specifically including
biosimilars thereof, which mentions different methods, for
example filtration (EP3334747). This application is also cur-
rently under examination. Amgen filed several international
applications as well for a liquid pharmaceutical composition
for trastuzumab and on a lyophilized pharmaceutical formula-
tion for trastuzumab and other molecules (WO2018201064,
WO2018200533, and WO2019055357).
2.3. Case study on bevacizumab
Bevacizumab is a humanized monoclonal antibody used in the
treatment of colon, rectum, breast, lung, kidney, ovary, and cervix
cancer due to its ability to attach to and inhibit the biological
activity of vascular endothelial growth factor (VEGF), a protein
responsible for the growth of blood vessels.41 In Europe, bevaci-
zumab has been marketed by Roche under the trade name
Avastin® since 2005. Patent and regulatory exclusivities on
Avastin® in Europe will protect the product until at least
June 2020, but possibly even longer (23rd of January 2022).
Already in 2018, a biosimilar to bevacizumab was approved for
use in the European Union, i.e., Mvasi® (Amgen), and also more
recently, in February 2019, Zirabev® (Pfizer) was approved.25
Marketing of these biosimilars will be delayed until relevant
patents and regulatory exclusivities have expired.
As was the case for trastuzumab, also the discovery of
bevacizumab is related to Genentech’s patent on chimeric
antibodies (EP0125023, filed on April 6, 1984) and PDL
Biopharma’s patent on humanized antibody production
(EP0451216, filed on December 28, 1989). For the latter,
Genentech again received a license from PDL Biopharma,
now for its development of bevacizumab.
The basic patent on bevacizumab, EP0666868, claiming the
use of anti-VEGF monoclonal antibodies for the treatment of
cancer, was filed on October 28, 1992 by Genentech, and
maintained in amended form in 2006 after an opposition
procedure, where the opponent asked the revocation of the
patent based on lack of novelty and inventive step, insuffi-
ciency of disclosure and added subject matter. Three divi-
sional applications were filed off of the basic patent, of
which one was related to the use of a human VEGF antagonist
for the treatment of non-neoplastic diseases where excessive
neovascularization plays a role and was the subject of several
patent litigation cases with Bayer and Regeneron’s VEGF
antagonist, aflibercept, for treatment of age-related macular
degeneration of the eye. All cases were eventually settled.
Already on March 28, 1996, Genentech also claimed the use
of a human VEGF antagonist in the treatment of age-related
macular degeneration (EP817648). However, the claimed
indication has never been added to the label of Avastin®,
although locally injected bevacizumab is known to be used
off-label for this indication.42 A next-generation product,
ranibizumab (Lucentis®), which is an antibody fragment
derived from the same murine monoclonal antibody as bev-
acizumab, was developed specifically for the treatment of age-
related macular degeneration.
On April 3, 1998, EP0973804 was filed by Genentech on
a variant of an earlier developed anti-VEGF antibody, which
is claimed to have stronger binding affinity. No opposition to
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this patent was filed. Later, an SPC for Lucentis® (ranibizu-
mab) was obtained on this patent. Six divisional applications
were filed, of which, EP1325932, claiming humanized anti-
VEGF antibodies with specific properties, was extended on
a national level with an SPC for Avastin®.
On August 17, 2007, Roche filed EP2056874, claiming the
use of bevacizumab for prevention and reduction of metasta-
sis in a patient with relapsed HER2 positive breast cancer.
One divisional application was filed: EP2441472. Both patents
were revoked based on grounds of lack of inventive step after
opposition proceedings from what we assume are companies
that were at that time developing a biosimilar.
On November 20, 2009, Roche filed EP2361085, claiming
the use of bevacizumab for the treatment of recurrent or
metastatic breast cancer, together with chemotherapy. The
patent was maintained in amended form in 2018 after the
opposition of Pfizer, amongst others. Two divisional applica-
tions were filed, which seem to contain similar claims. For the
first divisional application, EP2752189, an appeal procedure is
ongoing against the decision to revoke the patent based on
grounds of lack of inventive step after opposition from 10
opponents, including Pfizer. For the second divisional appli-
cation, EP3178478, examination is still in progress.
For Avastin®, a number of patent applications have also
been filed, which may or may not be granted, on humanizing
anti-VEGF antibodies, the combination of bevacizumab with
an anti-neoplastic composition, protein purification, preven-
tion of disulfide bond reduction, prediction of the risk on
a cardiovascular event, monitoring and diagnostic methods,
aqueous formulations, the use in treatment of (platinum
resistant) ovarian, peritoneal, and fallopian tube cancer, and
the use in treatment of (proneural subtype) glioblastoma
together with chemo and radiotherapy (Table A2).
Biosimilar developers are also seeking protection for incre-
mental innovation. On August 12, 2016, Amgen filed
EP3334747, claiming a method for the production of an aqu-
eous solution for, amongst other molecules, bevacizumab and
its biosimilars, which can be obtained via filtration (cfr. tras-
tuzumab). Examination of this application is in progress.
2.4. Case study on cetuximab
Cetuximab is a chimeric (mouse/human) monoclonal anti-
body used in the treatment of colon, rectum, and head and
neck cancer, due to its affinity for epidermal growth factor
receptor (EGFR), a protein involved in cell growth and pre-
sent on the cell surfaces of many colorectal and squamous cell
cancers.43 In Europe, cetuximab has been marketed by Merck
KGaA under the trade name Erbitux®. Patents and regulatory
exclusivity rights on this product have expired since
September 14, 2014. To date, no biosimilars to cetuximab
have been approved for use in the European Union.25
On September 15, 1989, Rorer International filed EP0359282,
claiming a monoclonal antibody that binds to EGFR, composi-
tions that effectively inhibit human tumor cell growth (when
these cells express human EGFR), and potential combinations
with an anti-neoplastic agent, such as doxorubicin or cisplatin.
In addition, a method of producing the monoclonal antibody
and therapeutic compositions thereof is claimed. Based on the
parent application, divisional application EP0667165 was filed,
owned by Rhône-Poulenc Rorer International holdings (after
a merger of Rorer with Rhône-Poulenc). The independent
claim specifically relates to the combination of a monoclonal
antibody that inhibits the growth of tumor cells that express
EGFR with an anti-neoplastic agent. After the publication of
grant of the patent on March 27, 2002, several parties (YM
BioSciences, The Scripps Research Institute, Amgen and
Abgenix) filed opposition against this patent based on lack of
novelty, lack of inventive step, insufficient disclosure, and added
subject matter. In May 2004, proceedings were stayed because
the ownership of the patent (EP0667165) was challenged by
Yeda, the commercialization arm of the Weizmann Institute of
Science. In 2004, Yeda filed an action in Germany to challenge
ownership of the patent in a case against Imclone (licensee),
Rhône Poulenc Rorer, and Aventis (formed after a merger of
Rhône Poulenc Rorer andHoechst). Yeda argued that the named
inventors on the patent, who were previously working for the
Weizmann Institute of Science, but moved to Meloy (later
Rorer), are not the inventors of the patent because they were
not involved in later steps and that the actual invention of the
synergistic effect of the combination of an anti-EGFR monoclo-
nal antibody with an anti-neoplastic agent was made by ‘the
Weizmann scientists’.44 Furthermore, Yeda accused Rorer of
using a draft publication of the Weizmann Institute of Science
to file its patent application. However, the action was dismissed
in Germany and an appeal of Yeda was rejected. This was also
the case in theUK, where Yeda had also started an action relating
to ownership. On December 7, 2007, they settled to resolve all
litigation matters, i.e., ongoing actions in the United States
(where Yeda had won its action related to ownership), Austria,
the United Kingdom, France, and Germany. The settlement
agreement also concluded that Sanofi (formed after a merger
with Aventis in 2004) and Yeda share ownership of the
European patent and shall jointly seek protection from an SPC,
and specifies license agreements of Yeda with Merck KGaA and
Amgen. Imclone, which already had a license from Rorer, also
received a license from Yeda. Sublicenses from Imclone to
Bristol-Myers Squibb and Merck KGaA also stayed valid. As
part of the agreement, Yeda received a single lump sum payment
from Imclone and Sanofi of US$ 60 million each, and continued
to receive royalties on the sales of Erbitux®. The opposition
procedure at the EPO was closed in 2011 after withdrawal of
opposition by the opponents.
Yeda and Aventis sought protection for cetuximab with an
SPC on EP0667165. In France, an SPC was approved already
in 2005 and was valid from the expiry of patent until
September 14, 2014.45 In the Netherlands and the UK, the
application was refused based on Article 3 of the SPC
Regulation (Regulation (EC) No 469/2009). The courts con-
cluded that the product of the marketing authorization
(Erbitux® – cetuximab), is not the product of the basic patent,
in which a combination of cetuximab with an anti-neoplastic
agent is claimed. An appeal from Yeda and Aventis was
rejected in both countries. The court of appeal (England &
Wales) referred the issue to the Court of Justice of the
European Union (CJEU), which answered that the issue
should indeed be interpreted as concluded by the national
court.
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Merck KGaA also filed several patent applications for
(concentrated) liquid and lyophilized formulations of cetux-
imab, a crystal form of cetuximab, and prediction methods for
patients’ respondence and side effects (Table A3).
Companies developing cetuximab biosimilars have applied
for patent protection of inventions related to cetuximab.
Amgen is linked to the development of a cetuximab
biosimilar46 and several patent applications for formulations
can be found. On October 5, 2007, Amgen filed EP2081553 on
a liquid formulation with increased stability consisting of
a buffer, a sugar, or polyol and, for example, cetuximab.
Also, on October 5, 2007, Amgen filed EP2094247 on
a solution with increased stability consisting of a buffer,
a divalent cation, a sugar, or polyol and, for example, cetux-
imab. Later, on August 12, 2016, EP3334747 was filed by
Amgen, which claims a production method for an aqueous
formulation obtained via a charged depth filter, which men-
tions several antibodies, including bevacizumab and cetuxi-
mab, and biosimilars of these molecules. The examination of
these three applications is in progress.
3. Discussion
This study focused on European patent applications on
selected therapeutic monoclonal antibodies. An overview of
effective market protection of nine monoclonal antibodies was
provided in Table 2, followed by more detailed case studies on
trastuzumab, bevacizumab, and cetuximab, while patent filing
strategies for tumor necrosis factor (TNF) inhibitors adalimu-
mab, etanercept and infliximab, and anti-CD20 monoclonal
antibody rituximab were already covered in the literature.30-32
The added value of our study lies, in addition to the inclusion
of new molecules, in providing examples of patents on biosi-
milars, and especially, in its focus on consequences of inno-
vator patent filing strategies for developers of biosimilar
medicines. Furthermore, in the discussion section, the results
of our overview are compared with findings for therapeutic
monoclonal antibodies earlier discussed in the literature.
The results of this study have shown that the duration of
effective market protection between the selected molecules is
rather large (10 to 17 y), and is determined by the basic patent
and SPC with possibly an extension via pediatric exclusivity
rights. An average market protection of 15 y for the different
molecules in this study is in line with the SPC Regulation,
which states that “the holder of both a patent and a certificate
should be able to enjoy an overall maximum of 15 years of
exclusivity from the time the medicinal product in question first
obtains authorization to be placed on the market in the
Community”.18 Only when the development time of
a molecule since the filing date of the (basic) patent exceeds
10 y, for example for cetuximab, this exclusivity period will be
shorter than 15 y, since the maximum duration of the SPC is
limited to 5 y, starting from the patent expiry date. Also, in
the case of the molecules in Table 2, the 10 y of regulatory
market exclusivity that are provided by the European
Commission at the moment of marketing authorization did
not seem to play a role in extending market protection pro-
vided by patents and SPCs, except for eculizumab (Soliris®),
an orphan medicinal product. Furthermore, the three case
studies illustrate the diversity of intellectual property strate-
gies applied to each molecule throughout its life cycle, with
not only patents on the antibody itself, but also patents on
indications, dosages, formulation/administration routes, and
biomarker testing. The development of combination products
and next-generation products was not explicitly covered in
the results section but is elaborated on as a potential competi-
tion strategy further in the discussion. It should be noted that
for the three case studies, multiple patent applications filed
after the basic patent were either not upheld by the EPO in
opposition procedures or granted patents were successfully
challenged by competitors in national patent litigation cases.
3.1. Competition strategies
To supplement protection from the basic patent, competition
strategies that were identified in earlier research can also be
found in this analysis, such as patent filings on a new indica-
tion, new formulation, or new dosage regimen, and develop-
ing and patenting combination and next-generation
products.10,47 These strategies are further elaborated in the
following paragraphs, together with a comparison with patent
filing strategies for molecules not included as a detailed case
study, for example, adalimumab (Humira®, AbbVie), inflixi-
mab (Remicade®, J&J), etanercept (Enbrel®, Pfizer) and ritux-
imab (MabThera®, Roche). An extensive patent filing strategy
was used by AbbVie to protect best-selling product Humira®
(adalimumab), with patents on formulations, dosages, new
indications, and the use of many divisional applications.31
A report by I-MAK has found that more than 70 European
patent applications have been filed for Humira®.48 Many
applications have been observed to be withdrawn, refused,
or revoked, as was also the case in our study for trastuzumab,
bevacizumab, and cetuximab. Patent filing strategies for
Remicade® (infliximab), Enbrel® (etanercept) and MabThera®
(rituximab) are considered to be less extensive but still follow
the expected strategies.30,32
3.1.1. Applying for patent protection on a new indication
A first strategy to extend protection for a product involves the
patenting of new indications. For instance, in addition to the
indication of cancer which was already clear in the basic
patent for bevacizumab, the use of bevacizumab for the treat-
ment of age-related macular degeneration, and specific can-
cers such as ovarian cancer, breast cancer, and glioblastoma
were patented over time.
This strategy can also be observed for rituximab, for which
first the use for non-Hodgkin lymphoma was patented, and
later patents were filed on its use for chronic lymphocytic
leukemia and rheumatoid arthritis.30 Also, for adalimumab,
varioussecond medical use patents were filed.31 It seems that
patents for new indications are often filed in combination
with a new dosage regimen or co-treatments.
3.1.2. Applying for patent protection on a new
formulation/administration route
A patent strategy may also be driven by development hurdles
such as formulation challenges. For instance, for cetuximab,
many efforts were made to find a stable formulation, with
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multiple patent applications filed. For the other molecules,
this seems to be limited to one per administration form.
Precedents demonstrate that patents on formulations of med-
icines are often ruled to be invalid due to lack of an inventive
step.2 We noticed in the analysis that indeed few formulation
patents applied for in the three case studies have been granted
or are active until the end of the 20-y patent protection term.
AbbVie has been successfully using this strategy to switch
patients on Humira® to a new formulation with less injection
pain, even though in Europe the patent for this formulation
was revoked after an opposition procedure.
Formulation patents for a new administration route can
also be of interest, such as for the later developed subcuta-
neous versions of trastuzumab and rituximab. Developing
a subcutaneous version of a medicine is typically more
patient-friendly, as it can be administered by the patient at
home, and an inconvenient physician visit can thus be
avoided. Also, administration times are shortened, which is
beneficial for patients and healthcare providers.49 A patent-
protected subcutaneous version of trastuzumab was approved
for use in the European Union in 2013,50 the year before the
expiry of market protection on intravenously administrated
trastuzumab and possible entry of biosimilars to the market.
A subcutaneous version of rituximab was developed as well,
which led to increased overall MabThera® market shares
(when summing market shares of both intravenously and
subcutaneously administered MabThera®) even though the
entry of biosimilars in 2017 negatively influenced the market
shares of intravenously administered rituximab.51 The devel-
opment of a subcutaneous version of an initially intravenously
administered medicine thus seems to be an effective defense
strategy. This strategy is now also employed by biosimilar
developers, with Celltrion receiving a positive EMA opinion
for its subcutaneously administered infliximab biosimilar in
September 2019.52
3.1.3. Applying for patent protection on a new dosage
regimen
A new dosage regimen can be claimed when having unex-
pected advantages over prior art regimens. Although there is
the possibility to leave the patented dosage regimen out of the
label of the biosimilar, still, biosimilar developers prefer to
rely on the dosage regimen as authorized for the reference
product.53 For Humira® (adalimumab), two patents for dosage
regimens for rheumatoid arthritis, as well as Crohn’s disease
and ulcerative colitis, were active at the moment of the loss of
basic protection on Humira®. Eventually, the patent litigation
cases that were started by several biosimilar developers were
settled, ensuring market entry of biosimilars in October 2018.
3.1.4. Filing divisional patent applications
The filing of divisional patent applications increases the com-
plexity of the product’s patent portfolio by adding new patent
applications that need to be taken into consideration and
leads to uncertainty of launch dates for competitor products,
even though the duration of patent protection is not extended
(and often the scope is even more limited). The use of many
divisional applications can be seen in the case studies on
trastuzumab and bevacizumab, both products of Roche, but
less in the case study on cetuximab (Merck KGaA).
AbbVie has made extensive use of this strategy to increase
complexity for its competitors.31 Furthermore, they have repeat-
edly withdrawn patents related to adalimumab before a decision
in a patent litigation case was taken, while replacing the content
(claims) of the original patent by several divisional patents to
spread the risk for loosing protection for one or another claim.
In 2017, the UK High Court has under special circumstances
taken a decision even after patents on Humira® were withdrawn
by AbbVie, and granted declarations to Fujifilm Kyowa Kirin
Biologics and Biogen that “their products were obvious and/or
anticipated at the claimed priority dates of certain of AbbVie’s
patents” ([2017] EWHC 395 (Pat)).
3.1.5. Development and applying for patent protection of
combination therapies
For treatment of cancer, combination therapies are often used
to improve efficacy in this heterogeneous disease.54 This is as
well reflected in the patent filing strategies of the selected case
studies relating to anti-cancer compounds, with, for example,
combinations with chemotherapy. Additionally, combinations
with other monoclonal antibodies are patented, for example
trastuzumab and pertuzumab (both from Roche), trastuzu-
mab and bevacizumab (both from Roche), and cetuximab and
matuzumab (both from Merck KGaA). This last combination
has not been commercialized, as the development of matuzu-
mab was stopped when clinical trial outcomes were not as
promising as expected.55 These limited examples might indi-
cate that companies are in the first instance looking for in-
house combination therapies. The TNF inhibitors and ritux-
imab are for their use as treatments for rheumatoid arthritis
often combined with methotrexate, and also patented as such.
3.1.6. Development and applying for patent protection of
next-generation products
Although development and patenting of next-generation pro-
ducts, which are created via modifying the structure of
a previously developed molecule, are distinct from the patent
strategy for the innovator molecule itself, it can be seen as an
element in a competitive strategy for the company that devel-
oped the innovator product to protect its market share. Next-
generation products might have an improved efficacy and
safety profile but can come with a premium price relative to
standard therapy.47
Since the development and approval of Herceptin® (trastu-
zumab), Roche has worked on several new products related to
anti-HER2 antibodies, to protect its position in the oncology
area. One of these products is pertuzumab (Perjeta®),
a humanized mouse monoclonal antibody, which was granted
marketing authorization in the European Union on March 4,
2013 for treatment of early-stage and metastatic breast cancer
in combination with trastuzumab and docetaxel or traditional
chemotherapy.56 Another product of Roche is trastuzumab
emtansine (Kadcyla®), an antibody–drug conjugate approved
for use in the European Union since November 15, 2013 for
the treatment of breast cancer, after treatment with trastuzu-
mab and a taxane.57 This medicine can be regarded both as
a next-generation product and combination treatment.
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Furthermore, following the development of Avastin® (bevaci-
zumab), Roche patented ranibizumab for age-related macular
degeneration (which is not on the label of Avastin®).
3.2. Biosimilars
As the data in Table 1 indicate, the market entry of biosimi-
lars either did not happen for a number of years following the
expiry of market protection on the innovator product (for
trastuzumab, etanercept, rituximab) or did not yet happen
(for cetuximab). Regardless of barriers arising from patent
strategies, this may also be due to a number of factors, such
as the complexity of the manufacturing process (a market
access barrier for biosimilar monoclonal antibodies cited in
the literature)26 or, in the case of Erbitux® (cetuximab), the
fact that it is not a top 10 biological medicine by global sales.
Although it seems that mainly the basic patent and subsequent
SPC protection play a role in delayingmarket entry of biosimilars,
further patenting in addition to the basic patent might influence
competition with companies developing a biosimilar, as is shown
by different patent litigation cases. Table 3 summarizes whether
biosimilar market entry is hindered (delayed) by secondary
patents for each of the three case studies (trastuzumab, bevacizu-
mab, and cetuximab) and the four monoclonal antibodies dis-
cussed in previous articles (adalimumab, etanercept, infliximab,
and rituximab). In our case studies, the hurdle arising from
secondary patents was in particular clear for the case of trastuzu-
mab, where Pfizer actively pursued different patent litigation cases
against Genentech/Roche. Except for one patent on trastuzumab
where the decision to reject the patent was overturned in appeal,
biosimilar developers have won all identified opposition and
national patent litigation cases. This indicates that some patents
on trastuzumab were seen as a real hurdle for biosimilar entry, but
that biosimilar developers can challenge these patents and win.
For trastuzumab, eventually, all identified hurdles related to
patents were cleared, albeit for some patents later than the expiry
of basic patent protection in 2014, and this might explain why
biosimilars were not immediately available. On the other hand,
the first marketing authorization for a trastuzumab biosimilar was
only granted in 2017, so development hurdles might have also
played a role. Only one active patent on Herceptin® without an
ongoing challenge by third parties can be identified, i.e., for the
subcutaneous version of trastuzumab (until 2030), and this patent
does not block market entry for intravenously administered ver-
sions. Patents that would potentially protect Avastin® longer than
the basic protection have also been under attack by developers of
biosimilars. The only active patent identified claims the use in the
treatment of recurrent or metastatic breast cancer together with
chemotherapy (until 2029). Biosimilar developers will probably
have to market their product without this indication on the label.
Patents on other new indications have also been recently granted
for Avastin®, but opposition was still possible at the time of the
study (May 2019). As far as we can assess, for Erbitux® (cetux-
imab) no patent litigation cases were held with companies devel-
oping a biosimilar. The only patents found that are still active, are
one on a lyophilized formulation (until 2022) and one on a clinical
prediction method (until 2030). The delayed entry of cetuximab
biosimilars does not seem to be related to IP issues.
Several biosimilars for adalimumab entered the Europeanmar-
ket in October 2018, after expiry of the basic patent, SPC and
a 6-month pediatric extension, following a settlement agreement
including a non-exclusive license on patents for dosage regimens
for rheumatoid arthritis and inflammatory bowel disease.58
Marketing in the US will have to wait until 2023 when
a licensing agreement on formulation and dosage patents
starts.59 For MabThera® (rituximab), which lost basic protection
in 2013, two patents on secondmedical uses including new dosage
regimens were a substantial hurdle to overcome for biosimilar
developers. An appeal to revocation of one patent is still pending
in March 2020, however, biosimilars already launched in many
European countries after national invalidation of the patent or
after the decision by the EPO to revoke the patent during oral
proceedings in June 2018. In Belgium, marketing of Sandoz’s
rituximab biosimilar was further delayed up to September 2019
due to an ongoing infringement action. For infliximab, later
patents than the basic patent on Remicade® did not seem to
influence the market entry of biosimilars in Europe, although it
is suggested that a license has been given for the combination of
infliximab with methotrexate.32 Also, for etanercept, no major
hurdles related to secondary patents have been identified. Only
a patent covering a specific formulation has to be taken into
account, but this can be bypassed by biosimilar developers by
making a new formulation, as has been done by Samsung
Bioepis.32
3.3. Limitations and areas for future research
This study is subject to a number of limitations. First, the study
focused on product claims, including secondmedical use claims.
Some patents with process claims are not linked to a specific
product, and therefore not easy to identify. As patent claims on
the molecule itself and possible indications can be considered as
the most blocking for competitors, especially biosimilar pro-
ducts, this would probably not considerably affect the results of
this study. It cannot be excluded that some patents related to the
selected molecules have been overlooked. Still, the most relevant
patents were most likely revealed via the search on case law.
Second, it was not always clear whether licenses on a certain
Table 3. Summary of results on whether secondary patents are a hurdle to market entry of therapeutic monoclonal antibodies.
Brand name Active substance Secondary patents delaying market entry of biosimilars?
Humira® adalimumab Eventually no. All litigation cases were settled before expiry of SPC by grant of a non-exclusive licensing agreement.
Avastin® bevacizumab Probably no. It remains to be seen whether biosimilars launch in June 2020.
Erbitux® cetuximab No. Potential hurdles were not identified.
Enbrel® etanercept No. Potential hurdles were not identified.
Remicade® infliximab No. But, a licensing agreement might exist.
MabThera® rituximab Yes. But, these hurdles were overcome via patent litigation.
Herceptin® trastuzumab Yes. But, these hurdles were overcome via patent litigation.
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patent were given to a third party, as this is not always made
public. Third, we calculated the effective market protection since
approval by the EMA in Table 2, while products will also
undergo a pricing and reimbursement procedure before launch
on the market. However, as this is the case for all products,
calculating market protection starting from the grant of market-
ing authorization is a valid proxy. Fourth, we did not check for
each country whether an SPC was granted, and, if so, for which
time period it provided exclusivity. However, we can assume that
when an SPC was granted in one of the selected countries (the
UK, Germany, and France), this would considerably hinder
competitors. Fifth, the selection of case studies is limited to
oncology products. Nevertheless, results from the general over-
view in Table 2 and previous literature were considered when
drawing conclusions. Sixth, although identifying strategies of
companies based on filed patent applications may not provide
a complete picture as to why these decisions were taken, an
overview of identified patents nonetheless generates valuable
knowledge on how patent portfolios develop in practice.
Finally, the European perspective may be too narrow to analyze
patent strategies, since many patent litigation cases occur in the
US, where most of the revenue is made. As the IP system in the
US is substantially different from that in Europe, it was not
considered to be in the scope of this study.
The current analysis focused mainly on identifying patents
relevant to the innovator product. Areas for future research
could be to conduct a more elaborate claim analysis of the identi-
fied patents to define the scope of protection of the different
molecules. Also, follow-on strategies to protect the position of
the innovator company on the market, for example via next-
generation products and combinations with new or existing med-
icines could be worked out more in detail. An in-depth study of
biosimilars that are currently in development and subsequent
analysis of patent applications related to these biosimilars could
be of added value. In addition, a comparative analysis with the
small molecule market and entry of generics could be conducted
to study whether IP strategies and enforcement of patents in this
market differ from the biopharmaceutical market. Finally, IP
strategies other than patent strategies can be further studied, for
example the use of multiple brand names for the same biosimilar
product with only a difference in indications on the label to
potentially work around active second medical use patents of
the innovator product (i.e., ‘skinny labelling’).
4. Conclusion
For the selected monoclonal antibodies, the key protection
instruments are the basic patent and the additional protection
provided by the award of an SPC with possible pediatric
extension, which provide for an average effective market
protection of the innovator product of 15 y.
Biosimilar developers still face on a case-by-case basis
substantial hurdles arising from patents taken after the basic
patent, which need to be overcome in patent litigation cases
on a European or national level. These hurdles, however, seem
to be surmountable, given that many cases were observed to
have been won by biosimilar developers and agreements were
made to settle ongoing cases. For some patents on the inno-
vator product, the biosimilar developer can invent around this
patent, for example when claiming a specific formulation, but
this is often not possible for other patents, such as on
a specific dosage regimen. Patent protected new indications
can be ‘carved’ out of the label of the biosimilar to avoid
infringement and already launch the biosimilar on the market.
Also biosimilars can be protected by filing new patents and
these mainly pertain to new formulations.
5. Methods
First, the basic patent (i.e., the first patent that would provide
product-specific protection), SPC, and potential other exclu-
sivity rights were identified and listed for the selected ther-
apeutic monoclonal antibodies in Europe, which are included
in Table 1, alongside a calculation of the total years of protec-
tion the product has enjoyed or will have enjoyed since
marketing authorization in the European Union (Table 2).
The information in Table 2 was constructed via relevant
articles and searches for SPCs in the national patent registers
of the UK, Germany and France, which can be considered as
highly valued markets for pharmaceutical companies. Also,
these databases are well established and publicly accessible.
Then, specific cases for a more in-depth study were chosen
based on added value toward previously published papers discuss-
ing patents on monoclonal antibodies, and the total years of
market protection of a product, which was calculated in the first
part. More particularly, trastuzumab, with a period of protection
of the reference product that seems average relative to other
selected molecules (14 y), bevacizumab, with a relatively long
period of protection of the reference product (17 y), and cetux-
imab, with a more limited period of protection of the reference
product (10 y), were chosen. Patent strategies for the innovator
products of adalimumab, etanercept, infliximab, and rituximab
have been previously described in the literature30-32 and were
therefore not included as case studies. Also, ranibizumab and
eculizumab were considered less relevant to study in-depth, as
these molecules are still patent protected, and to date no biosimi-
lars of these molecules are approved for marketing in the
European Union.
Two types of strategies were analyzed in the different case
studies: 1) the strategy of the innovator company to apply for
and enforce their patents and defend their product and mar-
ket share, and 2) the strategy of the biosimilar developer to
declare a patent invalid, claim non-infringement, or to invent
around patents on the reference product and potentially apply
for a new patent. A list of patents on the reference product
and the current status was prepared. For patents related to
biosimilars, we determined whether new patents were filed
and what type of inventions were claimed.
A two-step approach was used to obtain detailed informa-
tion on the selected cases: 1) an exploratory literature review,
and 2) a database analysis.
5.1. Exploratory literature review
An exploratory literature search in PubMed was conducted to (1)
search patent landscape analyses to learn from their methodology,
and (2) identify articles indicating patent numbers of monoclonal
antibodies and relevant case law. The search strategy included
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different combinations of the following terms: ‘Patents as Topic
[Mesh]’, ‘Biological’, ‘Europe’, ‘Antibody, monoclonal [Mesh]’,
and international nonproprietary and brand names of the selected
molecules. Articles could be published in English or Dutch.
European Regulations and Directives, guidelines, and
books known to the authors were searched for relevant infor-
mation on how to patent/claim a therapeutic monoclonal
antibody and possible intellectual property strategies. Case
law on relevant biological products was also searched on the
internet.
5.2. Database analysis
In addition to internet searches, the Darts-ip database60 was
used to search for relevant case law. Case law was studied to
determine which patents have been used to hinder market
access of biosimilars and which arguments are used in oppo-
sition, appeal, and national patent litigation processes. For
each of the molecules included in an in-depth case study,
a general patent search was performed by active ingredient
and Europe as a jurisdiction.
To supplement European patent numbers that were linked to
case law and found via the Darts-ip database, the Derwent
Innovation patent database61 was used to search for pending
patent applications and granted patents on a specific product.
Also, ‘dead’ patents (expired, not maintained, elapsed, revoked)
and withdrawn or refused patent applications were taken into
consideration. Different search terms were used depending on
the product investigated, e.g., the international nonproprietary
name, description of function or indication, US patent number,
often combined with the known applicant. Patents were also
screened for reference to earlier patents. In addition, different
synonyms were adopted. A template was used to make an over-
view of the following information: Product, title, patent number,
assignee/applicant, application date, priority date, publication
date, abstract, number of claims, claims, legal status, selected
European Member states, and other characteristics. In addition,
Espacenet, the public patent database of the EPO, and the
European patent register with publicly available procedural infor-
mation were consulted.62,63
Searches for patents and case law were performed between
December 2018 and May 2019.
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Appendices
Table A1. A non-exhaustive list of patents related to Herceptin® (trastuzumab) as of May 2019.
Subject Patent number
Date of
filing Applicant Status
Chimeric Ab EP0125023 06.04.1984 Genentech Expired on 06.04.2004
Humanized Ab production EP0451216 (parent) 28.12.1989 PDL
BioPharma
Expired on 28.12.2009
EP0939127 Expired on 28.12.2009
EP1477497 Expired on 28.12.2009
EP1491556 Expired on 28.12.2009
EP0682040 Revoked
Basic patent EP0590058 (parent) 15.06.1992 Genentech Expired on 15.06.2012
EP1400536 Withdrawn
EP0940468 Withdrawn
Freeze-dried formulation EP0845997 (parent) 23.07.1996 Genentech Withdrawn
EP1516628 Expired on 23.07.2016. Invalid in Norway and UK.
EP2275119 Expired on 23.07.2016. Invalid in UK.
Use in treatment of malignant breast cancer, with
taxoid
EP1037926 (parent) 10.12.1998 Genentech Revoked. Invalid in UK.
EP1947119 Deemed to be withdrawn
EP2275450 Withdrawn
EP2277919 Withdrawn
Compositions EP1075488 (parent) 03.05.1999 Genentech Expired on 03.05.2019
EP1308455 Expired on 03.05.2019. Invalid in Belgium, UK,
Germany.
EP1308456 Expired on 03.05.2019
Use in treatment (before/after surgery) EP1187632 09.05.2000 Genentech Revoked
Dosages EP1210115 (parent) 25.08.2000 Genentech Revoked. Invalid in UK.
EP2111870 Withdrawn
EP2110138 Withdrawn
Use in screened cancer patients EP1282443 (parent) 18.05.2001 Genentech Revoked
EP2116262 Withdrawn
Method for purification EP1648940 (parent) 24.06.2004 Genentech Granted. Appeal to revocation ongoing.
EP3095793 Examination in progress
Method for prevention of disulfide bond reduction EP2188302 (parent) 08.07.2008 Genentech Granted. Opposition procedure ongoing.
EP2586788 Granted. Opposition procedure ongoing.
EP3327026 Examination requested
Subcutaneous formulation EP2459167 (parent) 28.07.2010 Roche Active until 28.07.2030
EP2687202 Examination ongoing
Ab, antibody.
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Table A3. A non-exhaustive list of patents related to Erbitux® (cetuximab) as of May 2019.
Subject Patent number Date of filing Applicant Status
Anti-EGFR mAb EP0359282 (parent) 15.09.1989 Rorer International Expired on 15.09.2009
EP0667165 Expired on 15.09.2009
Liquid formulation EP1406658 18.06.2002 Merck Deemed to be withdrawn
Lyophilized formulation EP1455824 25.11.2002 Merck Active until 25.11.2022
Aqueous composition EP1687031 26.10.2004 Merck Revoked
Crystal form EP1686961 (parent) 12.11.2004 Merck Refused
EP1974723 Deemed to be withdrawn
Process for highly concentrated formulation EP1713502 27.01.2005 Merck Deemed to be withdrawn
Prediction method EP1869208 12.04.2006 Merck Refused
Prediction method EP1934599 (parent) 11.10.2006 Merck Deemed to be withdrawn
EP2251688 Deemed to be withdrawn
Prediction method EP2443252 15.06.2010 Merck Active until 15.06.2030
mAb, monoclonal antibody; EGFR, epidermal growth factor receptor.
Table A2. A non-exhaustive list of patents related to Avastin® (bevacizumab) as of May 2019.
Subject Patent number Date of filing Applicant Status
Chimeric Ab EP0125023 06.04.1984 Genentech Expired on 06.04.2004
Chimeric Ab production EP0451216 (parent) 28.12.1989 PDL BioPharma Expired on 28.12.2009
EP0939127 Expired on 28.12.2009
EP1477497 Expired on 28.12.2009
EP1491556 Expired on 28.12.2009
EP0682040 Revoked
Basic patent (use of anti-VEGF antibody for treatment of cancer) EP0666868 (parent) 28.10.1992 Genentech Expired on 28.10.2012
EP1167384 Expired on 28.10.2012
EP1238986 Expired on 28.10.2012
EP1975181 Revoked
Use in treatment of AMD EP817648 (parent) 28.03.1996 Genentech Expired on 28.03.2016
EP1506787 Expired on 28.03.2016
EP1627643 Deemed to be withdrawn
Variant anti-VEGF antibody EP0973804 (parent) 03.04.1998 Genentech Expired on 03.04.2018
EP1325932 Expired on 03.04.2018
EP1787999 Expired on 03.04.2018
EP1650220 Expired on 03.04.2018
EP2301580 Expired on 03.04.2018
EP2338915 Deemed to be withdrawn
EP2336190 Deemed to be withdrawn
Anti-VEGF antibody EP0971959 (parent) 03.04.1998 Genentech Expired on 03.04.2018
EP1695985 Expired on 03.04.2018
Combination with chemo EP1629010 28.05.2004 Genentech Withdrawn
Method for purification EP1648940 (parent) 24.06.2004 Genentech Granted. Appeal to revocation ongoing.
EP3095793 Examination in progress
Use for metastasis in breast cancer EP2056874 (parent) 17.08.2007 Roche Revoked
EP2441472 Revoked
Method for prevention of disulfide bond reduction EP2188302 (parent) 08.07.2008 Genentech Granted. Opposition procedure ongoing.
EP2586788 Granted. Opposition procedure ongoing.
EP3327026 Examination requested
Prediction CV event EP2321651 23.07.2009 Roche Granted. Opposition procedure ongoing.
Use for breast cancer, with chemo EP2361085 (parent) 20.11.2009 Roche Active until 20.11.2029
EP2752189 Granted. Opposition procedure ongoing.
EP3178478 Examination in progress
Monitoring EP2464744 13.08.2010 Roche Deemed to be withdrawn
Diagnostic method EP2478114 16.09.2010 Roche Deemed to be withdrawn
Formulation EP2515941 20.12.2010 Roche Examination in progress
Use in ovarian cancer EP2539367 (parent) 22.02.2011 Roche Refused
EP3064509 Examination in progress
Monitoring EP2783015 19.11.2012 Roche Deemed to be withdrawn
Biomarker test EP2788769 03.12.2012 Roche Deemed to be withdrawn
Use in treatment ovarian cancer EP2825558 11.03.2013 Roche Granted
Use in treatment glioblastoma EP2882454 (parent) 06.08.2013 Roche Granted
EP3446709 Application published
Use in treatment glioblastoma EP3038647 29.08.2014 Roche Granted
Formulation EP3193932 15.09.2015 Roche Examination in progress
Monitoring EP3443120 14.04.2017 Roche Request for examination
Ab, antibody; VEGF, vascular endothelial growth factor; AMD, age-related macular degeneration; CV, cardiovascular.
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